Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Contemporary Risk Stratification of Acute Coronary Syndrome
Author(s): Gurleen Kaur , Swati Chand , Devesh Rai , et al Added: 1 year ago

MI/ACS
ACC 2018: Alirocumab in patients after acute coronary syndrome
Author(s): Deepak L Bhatt Added: 6 years ago
Deepak Bhatt discusses the ODYSSEY Outcomes trial - alirocumab in patients after acute coronary syndrome. Filmed by Radcliffe Cardiology on-site at the American College of Cardiology congress 2018 in Orlando, USA View more

MI/ACS
Role of High-sensitivity Cardiac Troponin in Acute Coronary Syndrome
Author(s): Mahesh Anantha Narayanan , Santiago Garcia Added: 3 years ago
Chest pain is one of the most common reasons for an emergency room (ER) visit in the US with almost 6 million ER visits annually.1 According to the fourth universal definition of MI, acute MI (AMI) requires a rise and/or fall in cardiac troponin (cTn) with at least one value above the 99th percentile upper reference limit.2,3 Cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are the… View more

MI/ACS

Intervention
Author(s): Judd E Hollander Added: 3 years ago
Ischemic heart disease is the leading cause of death among adults and one of the most common reasons for emergency department (ED) visits across the US. There are approximately five to seven million ED visits for acute chest pain syndromes annually; however, only 5% of these patients are ultimately diagnosed with acute myocardial infarction (AMI) and an additional 10% have non-AMI acute coronary… View more

MI/ACS
USC Discussion 2022: Vulnerable Plaque in Patients with ACS
Author(s): Farshad Forouzandeh , Aloke V Finn Added: 2 years ago
In this insightful discussion, Dr Aloke V Finn (CVPath Institute & University of Maryland, Baltimore, MD, US) and Dr Farshad Forouzandeh (Case Western Reserve University Cleveland, Cleveland, OH, US) discuss key questions relating to vulnerable plaque in patients with acute coronary syndrome: How has intravascular imaging improved our understanding of vulnerable plaques, and in which direction… View more

MI/ACS
Antiplatelet and Anticoagulation Therapy in ACS
Author(s): Colin T Phillips , Michael C Gavin Added: 3 years ago
Acute coronary syndrome (ACS) occurs most often when a vulnerable intracoronary plaque ruptures or erodes to expose a prothrombotic core, precipitating thrombus formation by way of platelet activation,1–3 The spectrum of ACS includes non-ST segment-elevation (NSTE) ACS, where a vulnerable plaque threatens downstream coronary perfusion manifest as an increase in symptom frequency and/or duration … View more

Prevention & Chronic Conditions

MI/ACS
ESC 23: The STOPDAPT-3 Study
Author(s): Masahiro Natsuaki Added: 7 months ago
ESC 23 — Dr Masahiro Natsuaki (Saga University, JP) discusses the short and optimal duration of dual antiplatelet therapy-3 Study (STOPDAPT-3) (NCT04609111). In the STOPDAPT-2 study, 1-month dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy was shown to provide benefits in bleeding reduction over a 12-month period, however, other trials have shown high rates of bleeding at… View more

MI/ACS

Intervention
Author(s): Atsushi Sakamoto , Anne Cornelissen , Yu Sato , et al Added: 2 years ago

Vascular Disease and Surgery
Author(s): Judd E Hollander Added: 3 years ago
Ischemic heart disease is the leading cause of death among adults and one of the most common reasons for emergency department (ED) visits across the US. There are approximately five to seven million ED visits for acute chest pain syndromes annually; however, only 5% of these patients are ultimately diagnosed with acute myocardial infarction (AMI) and an additional 10% have non-AMI acute coronary… View more

MI/ACS
Author(s): Alan S Maisel Added: 3 years ago
Acute coronary syndrome (ACS) and congestive heart failure (CHF) are significant health risks affecting a large part of the population. In both diseases, early detection and initiation of treatment significantly reduce the risk of serious adverse events and death. B-type natriuretic peptide (BNP) and myeloperoxidase (MPO) have both shown considerable utility in the early diagnosis of patients… View more

Heart Failure

MI/ACS